Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic
Phase of Trial: Phase I/II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Insomnia; Sleep disorders
- Focus Adverse reactions
- 29 Jun 2017 Planned number of patients changed from 40 to 30.
- 26 Jan 2017 Status changed from not yet recruiting to recruiting.
- 11 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 1 Aug 2016.